In Silico Factorial Screening and Optimization of Chitosan Based Gel for Urapidil Loaded Microparticle using Reduced Factorial Design

Author(s): Harekrishna Roy*, Bhabani S. Nayak*, Sisir Nandi

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 23 , Issue 10 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Objective: Literature study revealed the poor mechanical strength of chitosan-based microparticles. Our research aimed at developing sufficient strength of microparticle with a suitable concentration of chitosan and non-ionic surfactants such as poloxamer-188 (pluronic). It also aimed to develop and study the effect of variables for prepared microparticles utilizing insilico screening methodology, such as reduced factorial design, followed by optimization.

Methods: Preliminary trial batches were prepared with variable concentration of chitosan and poloxamer-188 utilizing cross-linked ion-gelation technique. A 20% w/v sodium citrate solution was used as a cross-linking solution. The resolution-IV of 24-1 reduced factorial design was selected to screen the possible and significant independent variables or factors in the dosage form design. A total number of eight runs were suggested by statistical software and responses were recorded. The responses such as spreadability, pH, viscosity and percentage of drug released at 12 h were considered in the screening study. Based on the result, selected factors were included in the optimization technique, including graphical and numerical methods.

Results: The signified factors based on reduced two-level factorial screening design with randomized subtype, were identified by Half-normal and Pareto chart. Mathematical fitting and analysis were performed by the factorial equation during the optimization process. The validation and fitting of models were suggested and evaluated by p-value, adjusted R2, and predicted R2 values. The significant and non-significant terms were evaluated, followed by finding the optimal concentration and region with yellow color highlighted in an overlay plot. Based on the data obtained by the overlay study, the final formulation batch was prepared and the observed value was found to be pretty much nearer as compared to predicted values. Drug-polymer interaction study included attenuated total reflectance, differential scanning calorimetry, and X-Ray diffraction study.

Conclusion: The principal of the study design was based on finding the prefixed set parameter values utilizing the concept of in-silico screening technique and optimization with a minimal number of trials and study expenses. It concluded that Poloxamer-188 (0.94%), chitosan (2.38%), swelling time (1.81 h), and parts of chitosan (78.51%) in a formulation batch would fulfill the predetermined parameter with specific values.

Keywords: Sufficient strength of microparticle, in-silico factorial screening, optimization, reduced factorial design, chitosan, pluronic

[1]
Giaccotto, C.; Golec, J.; Vernon, J. New estimates of the cost of capital for pharmaceutical firms. J. Corp. Finance, 2011, 17(3), 526-540.
[http://dx.doi.org/10.1016/j.jcorpfin.2011.02.003]
[2]
Baranov, A.; Muzyko, E. Valuation of compound real options for investments in innovative projects in pharmaceutical industry. Procedia Econ., 2015, 27, 116-125.
[http://dx.doi.org/10.1016/S2212-5671(15)00980-6]
[3]
Roy, H.; Nandi, S. In-silico modeling in drug metabolism and interaction: current strategies of lead discovery. Curr. Pharm. Des., 2019, 25(31), 3292-3305.
[http://dx.doi.org/10.2174/1381612825666190903155935] [PMID: 31481001]
[4]
Hejaz, H.A.; Karaman, R. Drug Overview. Commonly Used Drug; Nova Science Publishers: New York, 2015, pp. 1-40.
[5]
Federsel, H.J. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective. Acc. Chem. Res., 2009, 42(5), 671-680.
[http://dx.doi.org/10.1021/ar800257v] [PMID: 19338294]
[6]
Coates, A.; Hu, Y.; Bax, R.; Page, C. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov., 2002, 1(11), 895-910.
[http://dx.doi.org/10.1038/nrd940] [PMID: 12415249]
[7]
Ji, Z.; Yan, K.; Li, W.; Hu, H.; Zhu, X. Mathematical and computational modeling in complex biological systems. Biomed Res. Int., 2017, 2017, 1-17.
[http://dx.doi.org/10.1155/2017/5958321]
[8]
Leelananda, S.P.; Lindert, S. Computational methods in drug discovery. Beilstein J. Org. Chem., 2016, 12(1), 2694-2718.
[http://dx.doi.org/10.3762/bjoc.12.267] [PMID: 28144341]
[9]
Patil, V.M.; Masand, N.; Gupta, S.P.V.; Masand, N.; Gupta, P S., GENIUS in silico screening technology for HCV drug discovery. Curr. Drug Discov. Technol., 2016, 13(4), 189-198.
[http://dx.doi.org/10.2174/1570163813666161006113011] [PMID: 27719657]
[10]
Boetker, J.; Raijada, D.; Aho, J.; Khorasani, M.; Søgaard, S.V.; Arnfast, L.; Bohr, A.; Edinger, M.; Water, J.J.; Rantanen, J. In silico product design of pharmaceuticals. Asian J. Pharm. Sci., 2016, 11(4), 492-499.
[http://dx.doi.org/10.1016/j.ajps.2016.02.010]
[11]
Mathias, N.R.; Crison, J. The use of modeling tools to drive efficient oral product design. AAPS J., 2012, 14(3), 591-600.
[http://dx.doi.org/10.1208/s12248-012-9372-3] [PMID: 22644702]
[12]
Eberle, V.A.; Häring, A.; Schoelkopf, J.; Gane, P.A.; Huwyler, J.; Puchkov, M. In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets. Drug Dev. Ind. Pharm., 2016, 42(5), 808-817.
[http://dx.doi.org/10.3109/03639045.2015.1078350] [PMID: 26307090]
[13]
Koradia, D.K.H; Parikh, R.D.; Koradia, H Application of plackett and burman design for screenin g of factors affecting albendazole nanocrystals. Curr. Nanomed., 2017, 7(2), 158-167.
[http://dx.doi.org/10.2174/2468187306666161129142950]
[14]
González-Rodríguez, M.L.; Mouram, I.; Cózar-Bernal, M.J.; Villasmil, S.; Rabasco, A.M. Applying the Taguchi method to optimize sumatriptan succinate niosomes as drug carriers for skin delivery. J. Pharm. Sci., 2012, 101(10), 3845-3863.
[http://dx.doi.org/10.1002/jps.23252] [PMID: 22806266]
[15]
Narayanan, K.; Subrahmanyam, V.; Venkata Rao, J. A fractional factorial design to study the effect of process variables on the preparation of hyaluronidase loaded PLGA nanoparticles. Enzyme Res., 2014, 2014, 1-10.
[http://dx.doi.org/10.1155/2014/162962]
[16]
Uy, M.; Telford, J. K. Optimization by Design of Experiment techniques. In 2009 IEEE Aerospace conference, Big Sky, MT,, 2009, 1-10.
[17]
Elazazy, M.S.; Issa, A.A.; Al-Mashreky, M.; Al-Sulaiti, M.; Al-Saad, K. Application of fractional factorial design for green synthesis of cyano-modified silica nanoparticles: Chemometrics and multifarious response optimization. Adv. Powder Technol., 2018, 29(5), 1204-1215.
[http://dx.doi.org/10.1016/j.apt.2018.02.012]
[18]
Komati, S.; Swain, S.; Rao, M.E.B.; Jena, B.R.; Unnam, S.; Dasi, V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bull. Fac. Pharm. Cairo Univ., 2018, 56(2), 129-145.
[http://dx.doi.org/10.1016/j.bfopcu.2018.09.002]
[19]
Nageeb El-Helaly, S.; Habib, B.A.; Abd El-Rahman, M.K. Resolution V fractional factorial design for screening of factors affecting weakly basic drugs liposomal systems. Eur. J. Pharm. Sci., 2018, 119, 249-258.
[http://dx.doi.org/10.1016/j.ejps.2018.04.028] [PMID: 29689287]
[20]
Roy, H. Box-behnken design for optimization of formulation variables for fast dissolving tablet of urapidil. Asian J. Pharm., 2018, 12(03), 946.
[21]
Sah, A.K.; Suresh, P.K.A.K; Suresh, P Loteprednol etabonate nanoparticles: optimization via Box-Behnken design response surface methodology and physicochemical characterization. Curr. Drug Deliv., 2017, 14(5), 676-689.
[http://dx.doi.org/10.2174/1567201813666160801125235] [PMID: 27480117]
[22]
Medscape. Hypertension: practice essentials, background, pathophysiology. https://emedicine.medscape.com/article/241381-overview2019 . Accessed November 28
[23]
World health organization. Hypertension.. https://www.who.int/news-room/fact-sheets/detail/hypertension2019 . Accessed December 02
[24]
Dooley, M.; Goa, K.L. Urapidil. A reappraisal of its use in the management of hypertension. Drugs, 1998, 56(5), 929-955.
[http://dx.doi.org/10.2165/00003495-199856050-00016] [PMID: 9829161]
[25]
US national library of medicine Urapidil-PubChem., https://pubchem.ncbi.nlm.nih.gov/compound/Urapidil 2019. Accessed November 24
[26]
Lengyel, M.; Kállai-Szabó, N.; Antal, V.; Laki, A.J.; Antal, I. Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci. Pharm., 2019, 87(3), 20.
[http://dx.doi.org/10.3390/scipharm87030020]
[27]
Nieva, C.A.; Villegas, M.; Cid, A.G.; Romero, A.I.; Bermúdez, J.M. Chitosan applications on pharmaceutical sciences: a review. Drug Deliv. Lett., 2019, 9(3), 167-181.
[http://dx.doi.org/10.2174/2210303109666190404143906]
[28]
Szymańska, E.; Winnicka, K. Stability of chitosan-a challenge for pharmaceutical and biomedical applications. Mar. Drugs, 2015, 13(4), 1819-1846.
[http://dx.doi.org/10.3390/md13041819] [PMID: 25837983]
[29]
Dumitriu, S. Polysaccharides: Structural Diversity and Functional Versatility; CRC Press, 2004.
[http://dx.doi.org/10.1201/9781420030822]
[30]
Kam, H.M.; Khor, E.; Lim, L.Y. Storage of partially deacetylated chitosan films. J. Biomed. Mater. Res., 1999, 48(6), 881-888.
[http://dx.doi.org/10.1002/(SICI)1097-4636(1999)48:6<881:AID-JBM18>3.0.CO;2-2] [PMID: 10556855]
[31]
Toffey, A.; Samaranayake, G.; Frazier, C.E.; Glasser, W.G. Chitin derivatives. I. Kinetics of the heat induced conversion of chitosan to chitin. J. Appl. Polym. Sci., 1996, 60(1), 75-85.
[http://dx.doi.org/10.1002/(SICI)1097-4628(19960404)60:1<75: AID-APP9>3.0.CO;2-S]
[32]
Roy, H.; Brahma, C.K.; Kumar, R.; Nandi, S. Formulation of saquinavir mesylate loaded microparticle by counterion induced aggregation method: Approach by hyperosmotic technique. Drug Invent. Today, 2013, 5(3), 259-266.
[http://dx.doi.org/10.1016/j.dit.2013.07.002]
[33]
Varu, R.K.; Khanna, A. Opportunities and challenges to implementing Quality by Design approach in generic drug development. J. Generic Med., 2010, 7(1), 60-73.
[http://dx.doi.org/10.1057/jgm.2009.37]
[34]
Batista, P.; Castro, P.; Madureira, A.R.; Sarmento, B.; Pintado, M. Development and characterization of chitosan microparticles-in-films for buccal delivery of bioactive peptides. Pharmaceuticals (Basel), 2019, 12(1), 32.
[http://dx.doi.org/10.3390/ph12010032] [PMID: 30791572]
[35]
Dholariya, Y.N.; Bansod, Y.B.; Vora, R.M.; Mittal, S.S.; Shirsat, A.E.; Bhingare, C.L. Design and optimization of bilayered tablet of Hydrochlorothiazide using the Quality-by-Design approach. Int. J. Pharm. Investig., 2014, 4(2), 93-101.
[http://dx.doi.org/10.4103/2230-973X.133058] [PMID: 25006554]
[36]
Zou, Y.; Fei, J.; Chen, L.; Dong, Q.; Li, H. Application of response surface methodology for improving the yield of 1,5-bis(ptoluenesulfonyl)- 3,7-dihydroxyoctahydro-1,5-diazocine. Curr. Org. Synth., 2019, 16(3), 398-404.
[http://dx.doi.org/10.2174/1570179415666181113144357] [PMID: 31984901]
[37]
Qiu, P.; Cui, M.; Kang, K.; Park, B.; Son, Y.; Khim, E.; Jang, M.; Khim, J. Application of Box-Behnken design with response surface methodology for modeling and optimizing ultrasonic oxidation of arsenite with H2O2. Open Chem., 2014, 12(2), 164-172.
[38]
Dantas, M.G.B.; Reis, S.A.G.B.; Damasceno, C.M.D.; Rolim, L.A.; Rolim-Neto, P.J.; Carvalho, F.O.; Quintans-Junior, L.J.; Almeida, J.R.G.d.S. Development and evaluation of stability of a gel formulation containing the monoterpene borneol. Sci. World J 2016, 2016, 1-4.
[http://dx.doi.org/10.1155/2016/7394685]
[39]
Shinde, U.; Pokharkar, S.; Modani, S. Design and evaluation of microemulsion gel system of nadifloxacin. Indian J. Pharm. Sci., 2012, 74(3), 237-247.
[http://dx.doi.org/10.4103/0250-474X.106066] [PMID: 23439454]
[40]
Sareen, R.; Kumar, S.; Gupta, G.D. Meloxicam carbopol-based gels: characterization and evaluation. Curr. Drug Deliv., 2011, 8(4), 407-415.
[http://dx.doi.org/10.2174/156720111795768013] [PMID: 21453256]
[41]
Pradhan, R.; Kim, S.Y.; Yong, C.S.; Kim, J.O. Preparation and characterization of spray-dried valsartan-loaded Eudragit® E PO solid dispersion microparticles. Asian J. Pharm. Sci., 2016, 11(6), 744-750.
[http://dx.doi.org/10.1016/j.ajps.2016.05.002]
[42]
Hester, M.W.; Usher, J. Factor screening experiments using fractional factorial split plot designs and regression analysis in developing a top-down nanomanufacturing system for recycling of welding rod residuals. Prod. Manuf. Res., 2017, 5(1), 118-139.
[http://dx.doi.org/10.1080/21693277.2017.1363006]
[43]
Hooda, A.; Nanda, A.; Jain, M.; Kumar, V.; Rathee, P. Optimization and evaluation of gastroretentive ranitidine HCl microspheres by using design expert software. Int. J. Biol. Macromol., 2012, 51(5), 691-700.
[http://dx.doi.org/10.1016/j.ijbiomac.2012.07.030] [PMID: 22903013]
[44]
Caccavo, D.; Cascone, S.; Lamberti, G.; Barba, A.A.; Larsson, A. Swellable hydrogel-based systems for controlled drug delivery; Smart Drug Delivery System, 2016, pp. 237-303.
[http://dx.doi.org/10.5772/61792]
[45]
Li, J.; Weber, E.; Guth-Gundel, S.; Schuleit, M.; Kuttler, A.; Halleux, C.; Accart, N.; Doelemeyer, A.; Basler, A.; Tigani, B.; Wuersch, K.; Fornaro, M.; Kneissel, M.; Stafford, A.; Freedman, B.R.; Mooney, D.J. Tough composite hydrogels with high loading and local release of biological drugs. Adv. Healthc. Mater., 2018, 7(9)e1701393
[http://dx.doi.org/10.1002/adhm.201701393] [PMID: 29441702]
[46]
Pramod, K.; Tahir, M.A.; Charoo, N.A.; Ansari, S.H.; Ali, J. Pharmaceutical product development: A quality by design approach. Int. J. Pharm. Investig., 2016, 6(3), 129-138.
[http://dx.doi.org/10.4103/2230-973X.187350] [PMID: 27606256]
[47]
Teja, S.; Damodharan, N. 23 Full factorial model for particle size optimization of methotrexate loaded chitosan nanocarriers: A design of experiments (DoE) approach. Biomed Res. Int., 2018, 2018, 1-9.
[48]
Lin, S-Y.; Chen, K-S.; Liang, R-C. Thermal micro ATR/FT-IR spectroscopic system for quantitative study of the molecular structure of poly (N-isopropylacrylamide) in water. Polymer (Guildf.), 1999, 40(10), 2619-2624.
[http://dx.doi.org/10.1016/S0032-3861(98)00512-6]
[49]
Mazurek-Wadołkowska, E.; Winnicka, K.; Czajkowska-Kośnik, A.; Czyzewska, U.; Miltyk, W. Application of differential scanning calorimetry in evaluation of solid state interactions in tablets containing acetaminophen. Acta Pol. Pharm., 2013, 70(5), 787-793.
[PMID: 24147356]
[50]
Randall, C.S.; Rocco, W.L.; Rico, P. XRD: XRD in pharmaceutical analysis: A versatile tool for problem-solving. Am. Pharm. Rev., 2010, 13(6), 52.
[51]
Stepanova, L.; Belskaya, O.; Salanov, A.; Serkova, A.; Likholobov, V. SEM study of the surface morphology and chemical composition of the MgAl-and MgGa-layered hydroxides in different steps of platinum catalysts Pt/Mg (Al, Ga) Ox synthesis. Appl. Clay Sci., 2018, 157, 267-273.
[http://dx.doi.org/10.1016/j.clay.2018.03.003]
[52]
Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 2018, 10(2), 57.
[http://dx.doi.org/10.3390/pharmaceutics10020057] [PMID: 29783687]
[53]
Berthold, A.; Cremer, K.; Kreuter, J. Collagen microparticles: carriers for glucocorticosteroids. Eur. J. Pharm. Biopharm., 1998, 45(1), 23-29.
[http://dx.doi.org/10.1016/S0939-6411(97)00119-7] [PMID: 9689532]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 10
Year: 2020
Page: [1049 - 1063]
Pages: 15
DOI: 10.2174/1386207323666200628110552
Price: $65

Article Metrics

PDF: 21
HTML: 1